{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:58:36Z","timestamp":1773413916295,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Clinical Science and Technology Climbing Program-\"Spark\u201dBasic Research Project, The Affiliated Cancer Hospital of Nanjing Medical University","award":["ZJ202213"],"award-info":[{"award-number":["ZJ202213"]}]},{"name":"789 Outstanding Talent Program of the Second Affiliated Hospital of Nanjing Medical University","award":["789ZYRC202080122"],"award-info":[{"award-number":["789ZYRC202080122"]}]},{"name":"Jiangsu Provincial Scientific Research and Health Project","award":["ZD2022005"],"award-info":[{"award-number":["ZD2022005"]}]},{"name":"Yishan Research Project of Jiangsu Cancer Hospital","award":["YSPY202401"],"award-info":[{"award-number":["YSPY202401"]}]},{"name":"Qunfeng Project of Jiangsu Cancer Hospital","award":["DFXK202504"],"award-info":[{"award-number":["DFXK202504"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82302974"],"award-info":[{"award-number":["82302974"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Youth Fund Projects of Jiangsu Province","award":["BK20210976"],"award-info":[{"award-number":["BK20210976"]}]},{"name":"Jiangsu Provincial Scientific research and Health Project for Women and Children","award":["F202004"],"award-info":[{"award-number":["F202004"]}]},{"name":"Research Project of Jiangsu Cancer Hospital","award":["RCQY202402"],"award-info":[{"award-number":["RCQY202402"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-02010-3","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:24:24Z","timestamp":1770639864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the optimal cutoff point and genomic characteristics for PARP inhibitor maintenance therapy in early recurrence of ovarian cancer"],"prefix":"10.1186","volume":"19","author":[{"given":"Luxin","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yourong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianzhong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuening","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"2010_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"key":"2010_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.9495","author":"G Caruso","year":"2025","unstructured":"Caruso G, Weroha SJ, Cliby W. Ovarian cancer: a review. JAMA. 2025. https:\/\/doi.org\/10.1001\/jama.2025.9495.","journal-title":"JAMA"},{"key":"2010_CR3","doi-asserted-by":"publisher","unstructured":"Bg PDSBNCGS, A K. Overall survival with maintenance Olaparib at a 7-Year Follow-Up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J Clin Oncology: Official J Am Soc Clin Oncol. 2023;41. https:\/\/doi.org\/10.1200\/JCO.22.01549.","DOI":"10.1200\/JCO.22.01549"},{"key":"2010_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S, Cropet C, Gonz\u00e1lez-Mart\u00edn A, Marth C, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol. 2023;34:681\u201392. https:\/\/doi.org\/10.1016\/j.annonc.2023.05.005.","journal-title":"Ann Oncol"},{"key":"2010_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann Oncol. 2024;35:981\u201392. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2241.","journal-title":"Ann Oncol"},{"key":"2010_CR6","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1200\/JCO-24-02834","volume":"43","author":"M Shah","year":"2025","unstructured":"Shah M, Chen T-Y, Ison G, Fiero MH, Zhang H, Gao X, et al. Overall survival and the evolving benefit-risk assessment for poly (ADP-ribose) polymerase inhibitors in advanced ovarian cancer. J Clin Oncol. 2025;43:2218\u201327. https:\/\/doi.org\/10.1200\/JCO-24-02834.","journal-title":"J Clin Oncol"},{"key":"2010_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13048-024-01381-9","volume":"17","author":"N Zhang","year":"2024","unstructured":"Zhang N, Zheng H, Gao Y, Shu T, Wang H, Cai Y. A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy. J Ovarian Res. 2024;17:55. https:\/\/doi.org\/10.1186\/s13048-024-01381-9.","journal-title":"J Ovarian Res"},{"key":"2010_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103694","volume":"9","author":"A Xu-Vuillard","year":"2024","unstructured":"Xu-Vuillard A, Guerin-Charbonnel C, Bocquet F, Cheeseman S, Kubelac PM, Zenatri M, et al. Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer. ESMO Open. 2024;9:103694. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103694.","journal-title":"ESMO Open"},{"key":"2010_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3773","volume":"371","author":"L Kuroki","year":"2020","unstructured":"Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773. https:\/\/doi.org\/10.1136\/bmj.m3773.","journal-title":"BMJ"},{"key":"2010_CR10","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","volume":"31","author":"RE Miller","year":"2020","unstructured":"Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31:1606\u201322. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2102.","journal-title":"Ann Oncol"},{"key":"2010_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13048-024-01400-9","volume":"17","author":"H Yuan","year":"2024","unstructured":"Yuan H, Li N, Wu L, Yao H. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients. J Ovarian Res. 2024;17:70. https:\/\/doi.org\/10.1186\/s13048-024-01400-9.","journal-title":"J Ovarian Res"},{"key":"2010_CR12","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for illumina sequence data. Bioinformatics. 2014;30:2114\u201320. https:\/\/doi.org\/10.1093\/bioinformatics\/btu170.","journal-title":"Bioinformatics"},{"key":"2010_CR13","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47:D941\u20137. https:\/\/doi.org\/10.1093\/nar\/gky1015.","journal-title":"Nucleic Acids Res"},{"key":"2010_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44:e131. https:\/\/doi.org\/10.1093\/nar\/gkw520.","journal-title":"Nucleic Acids Res"},{"key":"2010_CR15","doi-asserted-by":"publisher","first-page":"i333","DOI":"10.1093\/bioinformatics\/bts378","volume":"28","author":"T Rausch","year":"2012","unstructured":"Rausch T, Zichner T, Schlattl A, St\u00fctz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012;28:i333\u20139. https:\/\/doi.org\/10.1093\/bioinformatics\/bts378.","journal-title":"Bioinformatics"},{"key":"2010_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-024-01362-y","volume":"17","author":"I Barad\u00e1cs","year":"2024","unstructured":"Barad\u00e1cs I, Teutsch B, V\u00e1radi A, Bil\u00e1 A, Vincze \u00c1, Hegyi P, et al. PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials. J Ovarian Res. 2024;17:53. https:\/\/doi.org\/10.1186\/s13048-024-01362-y.","journal-title":"J Ovarian Res"},{"key":"2010_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.annonc.2024.10.828","volume":"36","author":"P Harter","year":"2025","unstructured":"Harter P, Marth C, Mouret-Reynier M-A, Cropet C, Lorusso D, Guerra-Al\u00eda EM, et al. Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1\/ENGOT-ov25 trial. Ann Oncol. 2025;36:185\u201396. https:\/\/doi.org\/10.1016\/j.annonc.2024.10.828.","journal-title":"Ann Oncol"},{"key":"2010_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.20517\/cdr.2022.13","volume":"5","author":"MJ Flynn","year":"2022","unstructured":"Flynn MJ, Ledermann JA. Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer. Cancer Drug Resist. 2022;5:424\u201335. https:\/\/doi.org\/10.20517\/cdr.2022.13.","journal-title":"Cancer Drug Resist"},{"key":"2010_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","volume":"156","author":"SC Cecere","year":"2020","unstructured":"Cecere SC, Giannone G, Salutari V, Arenare L, Lorusso D, Ronzino G, et al. Olaparib as maintenance therapy in patients with BRCA 1\u20132 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome. Gynecol Oncol. 2020;156:38\u201344. https:\/\/doi.org\/10.1016\/j.ygyno.2019.10.023.","journal-title":"Gynecol Oncol"},{"key":"2010_CR20","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","volume":"33","author":"JS Frenel","year":"2022","unstructured":"Frenel JS, Kim JW, Aryal N, Asher R, Berton D, Vidal L, et al. Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial. Ann Oncol. 2022;33:1021\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2022.06.011.","journal-title":"Ann Oncol"},{"key":"2010_CR21","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.annonc.2023.09.3110","volume":"34","author":"E Pujade-Lauraine","year":"2023","unstructured":"Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marm\u00e9 F, Lindemann K, et al. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT-ov38): a phase IIIb trial. Ann Oncol. 2023;34:1152\u201364. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.3110.","journal-title":"Ann Oncol"},{"key":"2010_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ygyno.2021.01.028","volume":"161","author":"S Liu","year":"2021","unstructured":"Liu S, Kasherman L, Fazelzad R, Wang L, Bouchard-Fortier G, Lheureux S, et al. The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2021;161:601\u201312. https:\/\/doi.org\/10.1016\/j.ygyno.2021.01.028.","journal-title":"Gynecol Oncol"},{"key":"2010_CR23","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: the first synthetic lethal targeted therapy. Science. 2017;355:1152\u20138. https:\/\/doi.org\/10.1126\/science.aam7344.","journal-title":"Science"},{"key":"2010_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ygyno.2022.12.009","volume":"169","author":"S Ehmann","year":"2023","unstructured":"Ehmann S, Shay K, Zhou Q, Iasonos A, Sonoda Y, Gardner GJ, et al. Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: a Memorial Sloan Kettering Cancer Center Team Ovary study. Gynecol Oncol. 2023;169:118\u201324. https:\/\/doi.org\/10.1016\/j.ygyno.2022.12.009.","journal-title":"Gynecol Oncol"},{"key":"2010_CR25","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","volume":"30","author":"A Fagotti","year":"2020","unstructured":"Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020;30:1657\u201364. https:\/\/doi.org\/10.1136\/ijgc-2020-001640.","journal-title":"Int J Gynecol Cancer"},{"key":"2010_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ygyno.2024.05.009","volume":"187","author":"OT Filippova","year":"2024","unstructured":"Filippova OT, Boecking K, Broach V, Gardner GJ, Sonoda Y, Chi DS, et al. Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study. Gynecol Oncol. 2024;187:80\u20134. https:\/\/doi.org\/10.1016\/j.ygyno.2024.05.009.","journal-title":"Gynecol Oncol"},{"key":"2010_CR27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/aogs.14319","volume":"101","author":"SM S\u00f8rensen","year":"2022","unstructured":"S\u00f8rensen SM, H\u00f8gdall C, Mosgaard BJ, Dalgaard MIR, Jensen MP, Fuglsang K, et al. Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2022;101:334\u201343. https:\/\/doi.org\/10.1111\/aogs.14319.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2010_CR28","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1200\/JCO.22.02765","volume":"41","author":"RE Bristow","year":"2023","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2023;41:4065\u201376. https:\/\/doi.org\/10.1200\/JCO.22.02765.","journal-title":"J Clin Oncol"},{"key":"2010_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ygyno.2017.05.005","volume":"146","author":"KH Eng","year":"2017","unstructured":"Eng KH, Morrell K, Starbuck K, Spring-Robinson C, Khan A, Cleason D, et al. Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer. Gynecol Oncol. 2017;146:52\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2017.05.005.","journal-title":"Gynecol Oncol"},{"key":"2010_CR30","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/1078-0432.CCR-13-1256","volume":"20","author":"D-J Cheon","year":"2014","unstructured":"Cheon D-J, Tong Y, Sim M-S, Dering J, Berel D, Cui X, et al. A collagen-remodeling gene signature regulated by TGF-\u03b2 signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res. 2014;20:711\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1256.","journal-title":"Clin Cancer Res"},{"key":"2010_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.canlet.2016.11.034","volume":"388","author":"K Auer","year":"2017","unstructured":"Auer K, Bachmayr-Heyda A, Aust S, Grunt TW, Pils D. Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer. Cancer Lett. 2017;388:158\u201366. https:\/\/doi.org\/10.1016\/j.canlet.2016.11.034.","journal-title":"Cancer Lett"},{"key":"2010_CR32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Integrated Genomic Analyses of Ovarian Carcinoma","year":"2011","unstructured":"Integrated Genomic Analyses of Ovarian Carcinoma. Nature. 2011;474:609\u201315. https:\/\/doi.org\/10.1038\/nature10166.","journal-title":"Nature"},{"key":"2010_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06214-z","volume":"14","author":"Y-B Wu","year":"2023","unstructured":"Wu Y-B, Li S-Y, Liu J-Y, Xue J-J, Xu J-F, Chen T, et al. Long non-coding RNA NRSN2-AS1 promotes ovarian cancer progression through targeting PTK2\/\u03b2-catenin pathway. Cell Death Dis. 2023;14:696. https:\/\/doi.org\/10.1038\/s41419-023-06214-z.","journal-title":"Cell Death Dis"},{"key":"2010_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09602-4","volume":"22","author":"H Wen","year":"2022","unstructured":"Wen H, Feng Z, Ma Y, Liu R, Ou Q, Guo Q, et al. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer. BMC Cancer. 2022;22:550. https:\/\/doi.org\/10.1186\/s12885-022-09602-4.","journal-title":"BMC Cancer"},{"key":"2010_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102021","volume":"86","author":"T-T Huang","year":"2020","unstructured":"Huang T-T, Lampert EJ, Coots C, Lee J-M. Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer. Cancer Treat Rev. 2020;86:102021. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102021.","journal-title":"Cancer Treat Rev"},{"key":"2010_CR36","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1158\/1535-7163.MCT-21-0873","volume":"21","author":"S Bai","year":"2022","unstructured":"Bai S, Taylor S, Jamalruddin MA, McGonigal S, Grimley E, Yang D, et al. Targeting therapeutic resistance and multinucleate giant cells in CCNE1-amplified HR-proficient ovarian cancer. Mol Cancer Ther. 2022;21:1473\u201384. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0873.","journal-title":"Mol Cancer Ther"},{"key":"2010_CR37","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1158\/1541-7786.MCR-23-0680","volume":"22","author":"JM Santiago-O\u2019Farrill","year":"2024","unstructured":"Santiago-O\u2019Farrill JM, Blessing Bollu A, Yang H, Orellana V, Pina M, Zhang X, et al. Crizotinib enhances PARP inhibitor efficacy in ovarian cancer cells and xenograft models by inducing autophagy. Mol Cancer Res. 2024;22:840\u201351. https:\/\/doi.org\/10.1158\/1541-7786.MCR-23-0680.","journal-title":"Mol Cancer Res"},{"key":"2010_CR38","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1146\/annurev-pathmechdis-012418-012917","volume":"15","author":"Y Wang","year":"2020","unstructured":"Wang Y, Hoang L, Ji JX, Huntsman DG. The SWI\/SNF complex mutations in gynecologic cancers: molecular mechanisms and models. Annu Rev Pathol. 2020;15:467\u201392. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-012418-012917.","journal-title":"Annu Rev Pathol"},{"key":"2010_CR39","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/his.14333","volume":"79","author":"E-Y Kang","year":"2021","unstructured":"Kang E-Y, Tessier-Cloutier B, Duggan MA, Stewart CJR, Lee C-H, K\u00f6bel M. Loss of ARID1B and SMARCB1 expression are specific for the diagnosis of dedifferentiated\/undifferentiated carcinoma in tumours of the upper gynaecological tract and cervix. Histopathology. 2021;79:160\u20137. https:\/\/doi.org\/10.1111\/his.14333.","journal-title":"Histopathology"},{"key":"2010_CR40","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41586-024-07250-1","volume":"628","author":"S Radko-Juettner","year":"2024","unstructured":"Radko-Juettner S, Yue H, Myers JA, Carter RD, Robertson AN, Mittal P, et al. Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI\/SNF. Nature. 2024;628:442\u20139. https:\/\/doi.org\/10.1038\/s41586-024-07250-1.","journal-title":"Nature"},{"key":"2010_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01153-8","volume":"9","author":"KC Wardrup","year":"2025","unstructured":"Wardrup KC, Hoffman J, Pandya MJ, Navarathna N, Tulapurkar ME, Padmanabhan A. ZNF217 promotes ovarian cancer progression by impacting multiple pivotal steps in the metastatic process. NPJ Precis Oncol. 2025;9:392. https:\/\/doi.org\/10.1038\/s41698-025-01153-8.","journal-title":"NPJ Precis Oncol"},{"key":"2010_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70031","volume":"6","author":"J Zhao","year":"2025","unstructured":"Zhao J, Yu Y, Ren W, Ding L, Chen Y, Yuan P, et al. Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: a multicenter, single-arm, phase II trial. MedComm. 2025;6:e70031. https:\/\/doi.org\/10.1002\/mco2.70031.","journal-title":"MedComm"},{"key":"2010_CR43","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1097\/SLA.0000000000002734","volume":"269","author":"VP Groot","year":"2019","unstructured":"Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA, et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg. 2019;269:1154\u201362. https:\/\/doi.org\/10.1097\/SLA.0000000000002734.","journal-title":"Ann Surg"},{"key":"2010_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-35092-w","volume":"13","author":"Z Shi","year":"2023","unstructured":"Shi Z, Chen B, Han X, Gu W, Liang S, Wu L. Genomic and molecular landscape of homologous recombination deficiency across multiple cancer types. Sci Rep. 2023;13:8899. https:\/\/doi.org\/10.1038\/s41598-023-35092-w.","journal-title":"Sci Rep"},{"key":"2010_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115320","volume":"219","author":"K Steger","year":"2025","unstructured":"Steger K, Fiegl H, Feroz B, Leitner K, Marth C, Hackl H, et al. Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) a study on TP53mut endometrial-, ovarian- and triple-negative breast cancer. Eur J Cancer. 2025;219:115320. https:\/\/doi.org\/10.1016\/j.ejca.2025.115320.","journal-title":"Eur J Cancer"},{"key":"2010_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2025.103830","volume":"149","author":"S Kulkarni","year":"2025","unstructured":"Kulkarni S, Seneviratne N, Tosun \u00c7, Madhusudan S. PARP inhibitors in ovarian cancer: mechanisms of resistance and implications to therapy. DNA Repair. 2025;149:103830. https:\/\/doi.org\/10.1016\/j.dnarep.2025.103830.","journal-title":"DNA Repair"},{"key":"2010_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189221","volume":"1879","author":"R Bi","year":"2024","unstructured":"Bi R, Chen L, Huang M, Qiao Z, Li Z, Fan G, et al. Emerging strategies to overcome PARP inhibitors\u2019 resistance in ovarian cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879:189221. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189221.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"2010_CR48","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40265-023-01934-0","volume":"83","author":"V Garg","year":"2023","unstructured":"Garg V, Oza AM. Treatment of ovarian cancer beyond PARP inhibition: current and future options. Drugs. 2023;83:1365. https:\/\/doi.org\/10.1007\/s40265-023-01934-0.","journal-title":"Drugs"},{"key":"2010_CR49","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","volume":"29","author":"SL Wethington","year":"2023","unstructured":"Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, et al. Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer. Clin Cancer Res. 2023;29:2800\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2444.","journal-title":"Clin Cancer Res"},{"key":"2010_CR50","doi-asserted-by":"publisher","first-page":"167574","DOI":"10.1016\/j.bbadis.2024.167574","volume":"1871","author":"Molecular mechanisms restoring","year":"2025","unstructured":"Molecular mechanisms restoring. Olaparib efficacy through ATR\/CHK1 pathway Inhibition in olaparib-resistant BRCA1\/2MUT ovarian cancer models. Biochimica et biophysica acta (BBA) -. Mol Basis Disease. 2025;1871:167574. https:\/\/doi.org\/10.1016\/j.bbadis.2024.167574.","journal-title":"Mol Basis Disease"},{"key":"2010_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V, et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun. 2020;11:3726. https:\/\/doi.org\/10.1038\/s41467-020-17127-2.","journal-title":"Nat Commun"},{"key":"2010_CR52","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2018.01.019","volume":"33","author":"C Sun","year":"2018","unstructured":"Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, et al. BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency. Cancer Cell. 2018;33:401-416.e8. https:\/\/doi.org\/10.1016\/j.ccell.2018.01.019.","journal-title":"Cancer Cell"},{"key":"2010_CR53","doi-asserted-by":"publisher","first-page":"6354","DOI":"10.1158\/1078-0432.CCR-21-1656","volume":"27","author":"SN Westin","year":"2021","unstructured":"Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, et al. Phase Ib dose expansion and translational analyses of Olaparib in combination with Capivasertib in recurrent endometrial, triple-negative breast, and ovarian cancer. Clin Cancer Res. 2021;27:6354\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1656.","journal-title":"Clin Cancer Res"},{"key":"2010_CR54","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202100054RR","volume":"35","author":"Z Liu","year":"2021","unstructured":"Liu Z, Lai J, Jiang H, Ma C, Huang H. Collagen XI alpha 1 chain, a potential therapeutic target for cancer. FASEB J. 2021;35:e21603. https:\/\/doi.org\/10.1096\/fj.202100054RR.","journal-title":"FASEB J"},{"key":"2010_CR55","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-19-4121","volume":"26","author":"S Lheureux","year":"2020","unstructured":"Lheureux S, Oaknin A, Garg S, Bruce JP, Madariaga A, Dhani NC, et al. EVOLVE: a multicenter open-label single-arm clinical and translational phase II trial of Cediranib plus Olaparib for ovarian cancer after PARP inhibition progression. Clin Cancer Res. 2020;26:4206\u201315. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-4121.","journal-title":"Clin Cancer Res"},{"key":"2010_CR56","doi-asserted-by":"publisher","unstructured":"Lee J-Y, Kim YN, Kim SW, Lim MC, Kim BG, Kim JW et al. A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01): first efficacy results of a 2-stage Simon\u2019s design. Proceedings of the 7th Biennial Meeting of Asian Society of Gynecologic Oncology, Thailand: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology; 2021, p. BO1. https:\/\/doi.org\/10.3802\/jgo.2021.32.S1.BO1","DOI":"10.3802\/jgo.2021.32.S1.BO1"},{"key":"2010_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100536","volume":"7","author":"L Musacchio","year":"2022","unstructured":"Musacchio L, Cicala CM, Camarda F, Ghizzoni V, Giudice E, Carbone MV, et al. Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? ESMO Open. 2022;7:100536. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100536.","journal-title":"ESMO Open"},{"key":"2010_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07311-3","volume":"15","author":"T Gao","year":"2024","unstructured":"Gao T, Li J, Cheng T, Wang X, Wang M, Xu Z, et al. Ovarian cancer-derived TGF-\u03b21 induces cancer-associated adipocytes formation by activating SMAD3\/TRIB3 pathway to establish pre-metastatic niche. Cell Death Dis. 2024;15:930. https:\/\/doi.org\/10.1038\/s41419-024-07311-3.","journal-title":"Cell Death Dis"},{"key":"2010_CR59","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ygyno.2024.07.688","volume":"190","author":"D Dai","year":"2024","unstructured":"Dai D, Li C, Xia H, Qi C, Lyu M, Yao Z, et al. Svil promotes ovarian cancer progression and epithelial-mesenchymal transition under hypoxic conditions through the TGF-\u03b2\/Smad pathway. Gynecol Oncol. 2024;190:167\u201378. https:\/\/doi.org\/10.1016\/j.ygyno.2024.07.688.","journal-title":"Gynecol Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-02010-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02010-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02010-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:53:26Z","timestamp":1773399206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-02010-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2010"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-02010-3","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board of Jiangsu Cancer Hospital in accordance with the Declaration of Helsinki (KY-2025-168). Written informed consent was collected from each patient upon sample collection according to the protocols approved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patients for publication of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}